Cipla is currently trading at Rs 331.85, up by 0.30 points or 0.09% from its previous closing of Rs 331.55 on the BSE.
The scrip opened at Rs 334.00 and has touched a high and low of Rs 334.00 and Rs 328.50 respectively. So far 41082 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 380.80 on 04-Jan-2011 and a 52 week low of Rs 273.60 on 06-Sep-2011.
Last one week high and low of the scrip stood at Rs 340.00 and Rs 320.60 respectively. The current market cap of the company is Rs 26620.86 crore.
The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 33.43% and 29.62% respectively.
Cipla has settled a trademark infringement case with German drug major Bayer Healthcare after it found Cipla's veterinary products were entering into the United States market, through Web site channels.
As per the settlement, Cipla will give up all profits it made from the sale of its DA Double Advantage, amounting in excess of $100,000, and discontinue all use of the trademark. It will also stop use of the trademark 'Advance' for a companion animal product and not make any product with the same formula as Bayer's Advantix, another patented flea preventative, during the remaining term of those patents.
Website operator Archipelago agreed to a consent decree, under which it is prohibited from selling DA Double Advantage and Advantix in the United States.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |